Abstract
Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced patients was 0.6%. Phenotypic testing showed that proI47A caused high-level lopinavir resistance (> 100-fold) and cross-resistance to amprenavir, whereas it caused hypersusceptibility to saquinavir. ProI47A should thus be considered the primary lopinavir resistance mutation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Carbamates / therapeutic use
-
Codon / genetics
-
Drug Resistance, Viral / genetics
-
Furans
-
Genotype
-
HIV Infections / drug therapy
-
HIV Infections / genetics*
-
HIV Protease Inhibitors / blood
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / drug effects
-
HIV-1 / genetics*
-
Humans
-
Indinavir / therapeutic use
-
Lopinavir
-
Mutation
-
Nelfinavir / therapeutic use
-
Phenotype
-
Pyrimidinones / blood
-
Pyrimidinones / therapeutic use*
-
Ritonavir / therapeutic use
-
Saquinavir / therapeutic use
-
Sulfonamides / therapeutic use
Substances
-
Carbamates
-
Codon
-
Furans
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Sulfonamides
-
Lopinavir
-
amprenavir
-
Indinavir
-
Nelfinavir
-
Saquinavir
-
Ritonavir